Condition
Advanced Synovial Sarcoma
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Terminated2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02650986Phase 1Active Not Recruiting
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT04965753Phase 1TerminatedPrimary
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
NCT03670069Phase 1Terminated
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Showing all 3 trials